ResMed

OverviewSuggest Edit

ResMed develops, manufactures and distributes medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders. It offers a number of products for sleep-disordered breathing and other respiratory disorders including airflow generators, diagnostic products, mask systems, headgear and other accessories. 

TypePublic
Founded1989
HQSan Diego, CA, USMap
Websiteresmed.com
Employee Ratings4More
Overall CultureA+More
View Jobs (358)

Recent NewsAll News

Latest Updates

Employees (est.) (Jun 2019)7,240(+22%)
Job Openings358
Revenue (FY, 2020)$3 B(+14%)
Share Price (Jun 2021)$218.6
Cybersecurity ratingCMore

Key People/Management at ResMed

Michael Mick Farrell

Michael Mick Farrell

CEO
Rob Douglas

Rob Douglas

President and Chief Operating Officer
David Pendarvis

David Pendarvis

Chief Administrative Officer, Global General Counsel
Jim Hollingshead

Jim Hollingshead

President, Sleep Business
McHale Richie

McHale Richie

Chief Transformation Officer
Raj Sodhi

Raj Sodhi

President, SaaS Business
Show more

ResMed Office Locations

ResMed has offices in San Diego, Alexandria, Rochester, Bella Vista and in 24 other locations
San Diego, CA, US (HQ)
9001 Spectrum Center Blvd
Alexandria, VA, US
Alexandria, VA, USA
Rochester, NY, US
1200 Brooks Ave
Bella Vista, AU
1 Elizabeth Macarthur Dr
Kontich, BE
50 Grote Steenweg
Beijing, CN
24 Dong San Huan Zhong Lu
Show all (28)

ResMed Financials and Metrics

ResMed Revenue

Embed Graph
View revenue for all periods
ResMed's revenue was reported to be $2.96 b in FY, 2020
USD

Revenue (Q3, 2021)

768.8m

Gross profit (Q3, 2021)

447.3m

Gross profit margin (Q3, 2021), %

58.2%

Net income (Q3, 2021)

(78.5m)

EBIT (Q3, 2021)

223.4m

Market capitalization (11-Jun-2021)

31.8b

Closing stock price (11-Jun-2021)

218.6

Cash (31-Mar-2021)

230.6m

EV

32.3b
ResMed's current market capitalization is $31.8 b.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

1.2b1.4b1.5b1.6b1.7b1.8b2.1b2.3b2.6b3.0b

Revenue growth, %

8%10%

Cost of goods sold

501.8m547.8m573.8m565.2m667.5m772.2m865.0m978.0m1.1b1.2b

Gross profit

741.3m820.7m940.7m989.8m1.0b1.1b1.2b1.4b1.5b1.7b
Quarterly
USDQ1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Revenue

282.0m306.0m313.3m314.8m332.7m349.1m339.7m376.5m383.6m357.7m384.3m397.8m380.4m423.0m422.5m411.6m454.5m453.9m465.5m530.4m514.2m523.7m601.3m591.6m588.3m651.1m662.2m681.1m736.2m769.5m751.9m800.0m768.8m

Cost of goods sold

108.1m120.0m130.8m129.7m134.0m138.6m131.1m143.8m144.1m129.7m135.6m146.0m143.1m159.7m171.1m173.0m188.0m194.0m196.3m221.3m214.5m218.1m251.5m247.3m245.2m267.4m270.3m276.0m309.0m319.8m313.3m337.5m321.5m

Gross profit

174.0m186.0m182.5m185.1m198.7m210.5m208.6m232.7m239.4m228.0m248.8m251.8m237.3m263.2m251.4m238.6m266.5m259.9m269.2m309.1m299.7m305.6m349.8m344.3m343.1m383.7m391.9m405.1m427.1m449.7m438.7m462.5m447.3m

Gross profit Margin, %

62%61%58%59%60%60%61%62%62%64%65%63%62%62%60%58%59%57%58%58%58%58%58%58%58%59%59%59%58%58%58%58%58%
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

735.3m809.5m876.0m905.7m717.2m731.4m821.9m188.7m147.1m463.2m

Accounts Receivable

274.4m283.2m318.3m359.6m362.6m450.5m483.7m528.5m474.6m

Prepaid Expenses

58.9m72.2m61.1m78.7m81.2m103.2m124.6m120.1m168.7m

Inventories

200.8m174.4m145.8m165.4m246.9m224.5m268.3m268.7m349.6m416.9m
Quarterly
USDQ1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Cash

540.0m616.2m671.7m610.1m723.2m776.1m890.6m958.3m1.0b976.6m972.7m938.6m881.7m880.7m866.3m822.1m658.8m718.5m781.7m788.1m827.3m811.1m858.9m704.3m230.2m149.5m146.5m172.2m204.1m352.9m421.4m255.9m230.6m

Accounts Receivable

225.8m235.1m251.9m251.1m238.8m267.9m266.5m281.4m293.5m282.4m301.6m337.6m328.6m340.4m345.5m327.2m331.7m358.2m347.1m384.0m413.6m431.4m482.9m498.4m463.7m477.2m511.4m493.8m528.0m554.9m464.9m509.4m525.0m

Prepaid Expenses

66.1m54.5m77.9m84.7m81.5m72.0m70.3m75.9m77.3m75.1m79.1m88.4m81.7m75.0m83.5m90.1m90.5m92.2m95.0m104.6m115.0m116.5m113.0m111.8m140.4m124.9m138.1m190.6m203.3m178.3m211.4m226.4m

Inventories

214.2m214.9m205.0m188.0m184.4m183.5m193.2m194.8m166.5m175.4m178.1m164.9m197.2m218.1m225.2m258.6m237.5m232.9m253.8m253.1m259.9m300.5m296.1m288.7m282.6m296.5m319.9m357.0m377.8m358.8m478.0m474.8m484.1m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

227.0m254.9m307.1m345.3m352.9m352.4m342.3m315.6m404.6m621.7m

Depreciation and Amortization

70.6m85.9m78.3m73.5m73.1m86.8m112.2m120.0m150.8m154.9m

Inventories

11.4m18.8m27.1m(15.9m)(99.5m)30.5m(41.6m)1.5m(84.2m)(69.9m)

Accounts Payable

(12.8m)72.8m29.6m3.1m85.8m46.4m34.6m200.7m(27.3m)(23.4m)
Quarterly
USDQ1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Net Income

56.7m115.2m53.4m50.5m113.4m178.0m71.3m149.2m234.1m80.9m167.6m257.5m83.3m174.4m91.0m80.4m170.9m259.4m76.1m152.8m240.7m86.1m95.7m205.8m105.7m230.4m335.8m120.1m280.7m443.8m178.4m357.9m279.4m

Depreciation and Amortization

15.6m33.0m2.7m20.4m43.4m63.4m18.7m37.9m58.6m17.9m36.5m53.6m18.6m37.5m18.4m39.9m59.8m27.8m55.5m84.0m29.6m58.9m88.3m30.4m66.5m108.2m38.0m77.1m116.3m39.5m80.0m120.0m

Inventories

(12.6m)(9.0m)4.2m8.9m12.8m(16.7m)(16.5m)9.9m(26.8m)(29.6m)(15.7m)(37.9m)(64.4m)225.2m(17.2m)8.8m26.0m(28.1m)(36.1m)(38.1m)(26.9m)(20.8m)(11.1m)(15.7m)(30.6m)(55.0m)(14.2m)(28.3m)(22.6m)(52.4m)(34.2m)(48.4m)

Accounts Payable

(19.2m)(14.9m)24.0m26.2m46.8m(13.3m)(10.8m)(20.0m)(24.3m)(37.9m)(20.8m)8.4m26.4m70.9m3.6m(5.7m)18.5m(18.7m)23.1m12.1m(15.6m)95.5m164.5m(99.0m)(125.2m)(106.7m)(30.1m)(88.9m)(57.3m)(61.3m)(99.3m)158.1m
show all
USDQ1, 2011

Financial Leverage

1.2 x
Show all financial metrics

ResMed Acquisitions / Subsidiaries

Company NameDateDeal Size
Propeller HealthDecember 07, 2018
MatrixCare IncNovember 05, 2018$750 m

ResMed Cybersecurity Score

Cybersecurity ratingPremium dataset

C

77/100

Learn more about our premium products
SecurityScorecard logo

ResMed Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

Learn more about our premium products
CSRHub logo

ResMed Online and Social Media Presence

ResMed's Trends

Embed Graph

ResMed Company Culture

  • Overall Culture

    A+

    82/100

  • CEO Rating

    A+

    95/100

  • Compensation

    A+

    90/100

  • Diversity

    B

    70/100

Learn more on Comparably

ResMed News and Updates

June 11, 2021

Thinking about trading options or stock in Cassava Sciences, GameStop, Adobe, ResMed, or Pfizer?

NEW YORK, June 11, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SAVA, GME, ADBE, RMD, and PFE. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different...
June 02, 2021

ResMed Announces Participation in the Goldman Sachs 42nd Annual Global Healthcare Conference

SAN DIEGO, June 02, 2021 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Rob Douglas, president and chief operating officer, will participate in a virtual fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8, 2021, beginning at approximate…
April 29, 2021

ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2021

- Year-over-year operating profit up 3%, non-GAAP operating profit up 2%
April 27, 2021

ResMed Announces Participation in the 23rd Annual Macquarie Australia Conference

SAN DIEGO, April 27, 2021 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Brett Sandercock, chief financial officer, will present virtually at the Macquarie Australia Conference on Wednesday, May 5, 2021, beginning at approximately 8:45 a.m. (Australian Eastern Standard Time) via …
October 27, 2020

Pulmonary Devices Market To Witness Huge Growth By 2027 with CAGR of 10.3% | ResMed, Masimo, Invacare Corporation, Koninklijke Philips N.V., Getinge AB

The North America pulmonary devices market is expected to reach US$ 16,637.44 million by 2027 from US$ 7,581.04 million in 2019. The market is anticipated to grow at a CAGR of 10.3% during 2019–2027. Posted via Industry Today. Follow us on Twitter @IndustryToday
July 28, 2020

Global Adult Ventilators Market Report 2020 Top Companies- Philips Healthcare, ResMed, Medtronic, Becton, Dickinson, Getinge, Dräger and more...

A new market study, titled “Global Adult Ventilators Market Professional Survey Report 2020”, has been featured on WiseGuyReports. Posted via Industry Today. Follow us on Twitter @IndustryToday
Show more

ResMed Blogs

October 07, 2019

Cerner and ResMed Join Forces to Connect Health Networks and the Home

Two industry leaders collaborate to improve out-of-hospital care transitions and chronic disease management
October 03, 2019

ResMed to Report First Quarter Fiscal 2020 Earnings on October 24, 2019

September 26, 2019

ResMed to Celebrate 30th Anniversary and 20 Years Listed on the New York Stock Exchange by Ringing the Opening Bell® on September 30, 2019

September 24, 2019

ResMed Named 2019 Dealmaker of the Year by Medtech Insight

5 key acquisitions drove global connected health leader’s award win
September 05, 2019

ResMed Announces Participation in the Bank of America Merrill Lynch Global Healthcare Conference

August 26, 2019

ResMed Announces Participation in the 17th Annual Morgan Stanley Global Healthcare Conference

Show more

 ResMed Frequently Asked Questions

  • When was ResMed founded?

    ResMed was founded in 1989.

  • Who are ResMed key executives?

    ResMed's key executives are Michael Mick Farrell, Rob Douglas and David Pendarvis.

  • How many employees does ResMed have?

    ResMed has 7,240 employees.

  • What is ResMed revenue?

    Latest ResMed annual revenue is $3 b.

  • What is ResMed revenue per employee?

    Latest ResMed revenue per employee is $408.4 k.

  • Who are ResMed competitors?

    Competitors of ResMed include Dentsply Sirona, Leica Microsystems and MED-EL.

  • Where is ResMed headquarters?

    ResMed headquarters is located at 9001 Spectrum Center Blvd, San Diego.

  • Where are ResMed offices?

    ResMed has offices in San Diego, Alexandria, Rochester, Bella Vista and in 24 other locations.

  • How many offices does ResMed have?

    ResMed has 28 offices.